Hyun Cheol Cheol Chung


Ontology type: schema:Person     


Person Info

NAME

Hyun Cheol Cheol

SURNAME

Chung

Publications in SciGraph latest 50 shown

  • 2021-09-18 Correction to: Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061 in GASTRIC CANCER
  • 2021-09-01 Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial in GASTRIC CANCER
  • 2021-08-07 Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061 in GASTRIC CANCER
  • 2021-04-11 Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia in TARGETED ONCOLOGY
  • 2021-03-20 Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab in GASTRIC CANCER
  • 2021-03-15 Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations in INVESTIGATIONAL NEW DRUGS
  • 2019-12-20 A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data in GASTRIC CANCER
  • 2019-06-22 Changes in taste and food preferences in breast cancer patients receiving chemotherapy: a pilot study in SUPPORTIVE CARE IN CANCER
  • 2019-05-16 Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer in GASTRIC CANCER
  • 2019-05-13 Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer in GASTRIC CANCER
  • 2019-03-25 Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study in GASTRIC CANCER
  • 2018-11-15 Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy in BMC CANCER
  • 2018-07-26 Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial in ANNALS OF SURGICAL ONCOLOGY
  • 2018-06-29 Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 in BRITISH JOURNAL OF CANCER
  • 2018-05-29 A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy in THE AAPS JOURNAL
  • 2018-05-29 Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study in BRITISH JOURNAL OF CANCER
  • 2018-02-07 Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma in BMC CANCER
  • 2017-12-04 Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer in CLINICAL EPIGENETICS
  • 2017-10-25 A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2017-06-22 The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status in GASTRIC CANCER
  • 2017-04-20 Prevalence and prognostic implications of psychological distress in patients with gastric cancer in BMC CANCER
  • 2017-03-28 A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors in INVESTIGATIONAL NEW DRUGS
  • 2017-02-27 Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer in BREAST CANCER RESEARCH AND TREATMENT
  • 2016-07-22 High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2016-07-08 Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma in BMC CANCER
  • 2016-02-02 Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma in ANNALS OF NUCLEAR MEDICINE
  • 2015-02-24 The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer in ANNALS OF SURGICAL ONCOLOGY
  • 2015-01-16 LAMC2 enhances the metastatic potential of lung adenocarcinoma in CELL DEATH & DIFFERENTIATION
  • 2014-08-09 Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2014-08-01 Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer in ANNALS OF SURGICAL ONCOLOGY
  • 2014-07-24 High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients in WORLD JOURNAL OF SURGICAL ONCOLOGY
  • 2014-04-09 Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: Randomized phase II multicenter trial in INVESTIGATIONAL NEW DRUGS
  • 2014-02-27 A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer in INVESTIGATIONAL NEW DRUGS
  • 2013-12-24 Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START) in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2013-12-06 S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial in BMC CANCER
  • 2013-08-23 Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer in BMC CANCER
  • 2013-03-30 Application of the Adjuvant! Online Model to Korean Breast Cancer Patients: An Assessment of Prognostic Accuracy and Development of an Alternative Prognostic Tool in ANNALS OF SURGICAL ONCOLOGY
  • 2013-02-10 Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer in NATURE MEDICINE
  • 2013-01-23 Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors in SUPPORTIVE CARE IN CANCER
  • 2012-10-12 Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience in BMC CANCER
  • 2012-07-30 Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells in BMC GENOMICS
  • 2012-04-27 Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent in INVESTIGATIONAL NEW DRUGS
  • 2011-12-02 Body image, sexual function and depression in Korean patients with breast cancer: modification by 5-HTT polymorphism in SUPPORTIVE CARE IN CANCER
  • 2011-05-13 A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy in INVESTIGATIONAL NEW DRUGS
  • 2011-04-05 Biweekly gemcitabine–paclitaxel, gemcitabine–carboplatin, or gemcitabine–cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial in BREAST CANCER
  • 2011-02-16 Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2011-02-16 Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2010-12-29 A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy in INVESTIGATIONAL NEW DRUGS
  • 2010-08-24 A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer in INVESTIGATIONAL NEW DRUGS
  • 2010-06-19 The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up in ANNALS OF SURGICAL ONCOLOGY
  • Affiliations

  • Yonsei University (current)
  • Ajou University Hospital
  • The University of Texas MD Anderson Cancer Center
  • Soonchunhyang University Hospital
  • Chonnam National University
  • Eli Lilly (Canada)
  • Seoul National University Hospital
  • Korea University Medical Center
  • Korean Cancer Study Group
  • Jiangsu Cancer Hospital
  • Huazhong University of Science and Technology
  • Aichi Cancer Center
  • Yonsei University Health System
  • Shizuoka Cancer Center
  • 307th Hospital of Chinese People’s Liberation Army
  • Harbin Medical University
  • St. Luke's Medical Center
  • Roche (United Kingdom)
  • Gangnam Severance Hospital
  • Institut de Cancérologie de l'Ouest
  • Bristol-Myers Squibb (France)
  • Gdańsk Medical University
  • Keimyung University
  • Faculdade de Medicina do ABC
  • Catholic University of Korea
  • Roche (Switzerland)
  • Cancer Hospital of Chinese Academy of Medical Sciences
  • Inha University Hospital
  • Bristol-Myers Squibb (United States)
  • Seoul St. Mary's Hospital
  • Asan Medical Center
  • Yanbian University Hospital
  • Ajou University
  • Centre Hospitalier Universitaire de Besançon
  • National Taiwan University Hospital
  • Seoul National University
  • Pfizer (Italy)
  • The Cancer Institute Hospital
  • Kyung Hee University
  • Institut Claudius Regaud
  • Yeungnam University Medical Center
  • University of Washington
  • Samsung Medical Center
  • CHA University
  • Chinese Academy of Medical Sciences & Peking Union Medical College
  • Universitair Ziekenhuis Leuven
  • Ospedale Policlinico San Martino
  • Severance Hospital
  • Sir Run Run Shaw Hospital
  • Peking University Cancer Hospital
  • Cornell University
  • Chungnam National University
  • National Cancer Center
  • Instituto Nacional de Enfermedades Neoplásicas
  • GlaxoSmithKline (United States)
  • Dr. Euryclides Hospital de Jesus Zerbini
  • Eli Lilly (United States)
  • University of California, Los Angeles
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "http://www.grid.ac/institutes/grid.15444.30", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411261.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.240145.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412678.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.14005.30", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.418787.5", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412484.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411134.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.497763.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.452509.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.33199.31", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410800.d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413046.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.415797.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.452349.d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410736.7", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.416846.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.419227.b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.459553.b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.418191.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.481843.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.11451.30", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412091.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.419034.b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411947.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.417570.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.459409.5", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411605.7", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.419971.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.414966.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413967.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.459480.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.251916.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411158.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412094.a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.31501.36", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.439132.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.486756.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.289247.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.417829.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413040.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.34477.33", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.414964.a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410886.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.506261.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410569.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410345.7", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.415562.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.415999.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412474.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5386.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.254230.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410914.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.419177.d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.418019.5", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.414380.a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.417540.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.19006.3e", 
            "type": "Organization"
          }
        ], 
        "familyName": "Chung", 
        "givenName": "Hyun Cheol Cheol", 
        "id": "sg:person.016554426212.74", 
        "identifier": [
          {
            "name": "orcid_id", 
            "type": "PropertyValue", 
            "value": "0000-0002-0920-9471"
          }
        ], 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016554426212.74", 
          "https://orcid.org/0000-0002-0920-9471"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2021-12-01T20:42", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/person/person_817.jsonl", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.016554426212.74'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.016554426212.74'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.016554426212.74'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.016554426212.74'


     

    This table displays all metadata directly associated to this object as RDF triples.

    135 TRIPLES      11 PREDICATES      70 URIs      8 LITERALS      3 BLANK NODES

    Subject Predicate Object
    1 sg:person.016554426212.74 schema:affiliation N9a617f33c33847ecbf546e7fd622e88a
    2 grid-institutes:grid.11451.30
    3 grid-institutes:grid.14005.30
    4 grid-institutes:grid.19006.3e
    5 grid-institutes:grid.240145.6
    6 grid-institutes:grid.251916.8
    7 grid-institutes:grid.254230.2
    8 grid-institutes:grid.289247.2
    9 grid-institutes:grid.31501.36
    10 grid-institutes:grid.33199.31
    11 grid-institutes:grid.34477.33
    12 grid-institutes:grid.410345.7
    13 grid-institutes:grid.410569.f
    14 grid-institutes:grid.410736.7
    15 grid-institutes:grid.410800.d
    16 grid-institutes:grid.410886.3
    17 grid-institutes:grid.410914.9
    18 grid-institutes:grid.411134.2
    19 grid-institutes:grid.411158.8
    20 grid-institutes:grid.411261.1
    21 grid-institutes:grid.411605.7
    22 grid-institutes:grid.411947.e
    23 grid-institutes:grid.412091.f
    24 grid-institutes:grid.412094.a
    25 grid-institutes:grid.412474.0
    26 grid-institutes:grid.412484.f
    27 grid-institutes:grid.412678.e
    28 grid-institutes:grid.413040.2
    29 grid-institutes:grid.413046.4
    30 grid-institutes:grid.413967.e
    31 grid-institutes:grid.414380.a
    32 grid-institutes:grid.414964.a
    33 grid-institutes:grid.414966.8
    34 grid-institutes:grid.415562.1
    35 grid-institutes:grid.415797.9
    36 grid-institutes:grid.415999.9
    37 grid-institutes:grid.416846.9
    38 grid-institutes:grid.417540.3
    39 grid-institutes:grid.417570.0
    40 grid-institutes:grid.417829.1
    41 grid-institutes:grid.418019.5
    42 grid-institutes:grid.418191.4
    43 grid-institutes:grid.418787.5
    44 grid-institutes:grid.419034.b
    45 grid-institutes:grid.419177.d
    46 grid-institutes:grid.419227.b
    47 grid-institutes:grid.419971.3
    48 grid-institutes:grid.439132.e
    49 grid-institutes:grid.452349.d
    50 grid-institutes:grid.452509.f
    51 grid-institutes:grid.459409.5
    52 grid-institutes:grid.459480.4
    53 grid-institutes:grid.459553.b
    54 grid-institutes:grid.481843.2
    55 grid-institutes:grid.486756.e
    56 grid-institutes:grid.497763.8
    57 grid-institutes:grid.506261.6
    58 grid-institutes:grid.5386.8
    59 schema:familyName Chung
    60 schema:givenName Hyun Cheol Cheol
    61 schema:identifier Nb1803d07f23f40a18993eaa09c56722d
    62 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016554426212.74
    63 https://orcid.org/0000-0002-0920-9471
    64 schema:sdDatePublished 2021-12-01T20:42
    65 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    66 schema:sdPublisher Ncd0b591e3261428daf8ef864cc009d00
    67 sgo:license sg:explorer/license/
    68 sgo:sdDataset persons
    69 rdf:type schema:Person
    70 N9a617f33c33847ecbf546e7fd622e88a schema:affiliation grid-institutes:grid.15444.30
    71 sgo:isCurrent true
    72 rdf:type schema:OrganizationRole
    73 Nb1803d07f23f40a18993eaa09c56722d schema:name orcid_id
    74 schema:value 0000-0002-0920-9471
    75 rdf:type schema:PropertyValue
    76 Ncd0b591e3261428daf8ef864cc009d00 schema:name Springer Nature - SN SciGraph project
    77 rdf:type schema:Organization
    78 grid-institutes:grid.11451.30 schema:Organization
    79 grid-institutes:grid.14005.30 schema:Organization
    80 grid-institutes:grid.15444.30 schema:Organization
    81 grid-institutes:grid.19006.3e schema:Organization
    82 grid-institutes:grid.240145.6 schema:Organization
    83 grid-institutes:grid.251916.8 schema:Organization
    84 grid-institutes:grid.254230.2 schema:Organization
    85 grid-institutes:grid.289247.2 schema:Organization
    86 grid-institutes:grid.31501.36 schema:Organization
    87 grid-institutes:grid.33199.31 schema:Organization
    88 grid-institutes:grid.34477.33 schema:Organization
    89 grid-institutes:grid.410345.7 schema:Organization
    90 grid-institutes:grid.410569.f schema:Organization
    91 grid-institutes:grid.410736.7 schema:Organization
    92 grid-institutes:grid.410800.d schema:Organization
    93 grid-institutes:grid.410886.3 schema:Organization
    94 grid-institutes:grid.410914.9 schema:Organization
    95 grid-institutes:grid.411134.2 schema:Organization
    96 grid-institutes:grid.411158.8 schema:Organization
    97 grid-institutes:grid.411261.1 schema:Organization
    98 grid-institutes:grid.411605.7 schema:Organization
    99 grid-institutes:grid.411947.e schema:Organization
    100 grid-institutes:grid.412091.f schema:Organization
    101 grid-institutes:grid.412094.a schema:Organization
    102 grid-institutes:grid.412474.0 schema:Organization
    103 grid-institutes:grid.412484.f schema:Organization
    104 grid-institutes:grid.412678.e schema:Organization
    105 grid-institutes:grid.413040.2 schema:Organization
    106 grid-institutes:grid.413046.4 schema:Organization
    107 grid-institutes:grid.413967.e schema:Organization
    108 grid-institutes:grid.414380.a schema:Organization
    109 grid-institutes:grid.414964.a schema:Organization
    110 grid-institutes:grid.414966.8 schema:Organization
    111 grid-institutes:grid.415562.1 schema:Organization
    112 grid-institutes:grid.415797.9 schema:Organization
    113 grid-institutes:grid.415999.9 schema:Organization
    114 grid-institutes:grid.416846.9 schema:Organization
    115 grid-institutes:grid.417540.3 schema:Organization
    116 grid-institutes:grid.417570.0 schema:Organization
    117 grid-institutes:grid.417829.1 schema:Organization
    118 grid-institutes:grid.418019.5 schema:Organization
    119 grid-institutes:grid.418191.4 schema:Organization
    120 grid-institutes:grid.418787.5 schema:Organization
    121 grid-institutes:grid.419034.b schema:Organization
    122 grid-institutes:grid.419177.d schema:Organization
    123 grid-institutes:grid.419227.b schema:Organization
    124 grid-institutes:grid.419971.3 schema:Organization
    125 grid-institutes:grid.439132.e schema:Organization
    126 grid-institutes:grid.452349.d schema:Organization
    127 grid-institutes:grid.452509.f schema:Organization
    128 grid-institutes:grid.459409.5 schema:Organization
    129 grid-institutes:grid.459480.4 schema:Organization
    130 grid-institutes:grid.459553.b schema:Organization
    131 grid-institutes:grid.481843.2 schema:Organization
    132 grid-institutes:grid.486756.e schema:Organization
    133 grid-institutes:grid.497763.8 schema:Organization
    134 grid-institutes:grid.506261.6 schema:Organization
    135 grid-institutes:grid.5386.8 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...